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Clinical application of induced pluripotent stem cells
(iPSCs) is limited by the low efficiency of iPSC deriva-
tion and the fact that most protocols modify the
genome to effect cellular reprogramming. Moreover,
safe and effective means of directing the fate of
patient-specific iPSCs toward clinically useful cell
types are lacking. Here we describe a simple, nonin-
tegrating strategy for reprogramming cell fate based
on administration of synthetic mRNA modified to
overcome innate antiviral responses. We show that
this approach can reprogram multiple human cell
types to pluripotency with efficiencies that greatly
surpass established protocols. We further show
that the same technology can be used to efficiently
direct the differentiation of RNA-induced pluripotent
stem cells (RiPSCs) into terminally differentiated
myogenic cells. This technology represents a safe,
efficient strategy for somatic cell reprogramming
and directing cell fate that has broad applicability
for basic research, disease modeling, and regenera-
tive medicine.618 Cell Stem Cell 7, 618–630, November 5, 2010 ª2010 Elsevier IncINTRODUCTION
The reprogramming of differentiated cells to pluripotency holds
great promise as a tool for studying normal development, while
offering hope that patient-specific induced pluripotent stem cells
(iPSCs) could be used to model disease or to generate clinically
useful cell types for autologous therapies aimed at repairing defi-
cits arising from injury, illness, and aging. Induction of pluripo-
tency was originally achieved by Yamanaka and colleagues by
enforced expression of four transcription factors, KLF4,
c-MYC, OCT4, and SOX2 (KMOS), by using retroviral vectors
(Takahashi et al., 2007; Takahashi and Yamanaka, 2006). Viral
integration into the genome initially presented a formidable
obstacle to therapeutic use of iPSCs. The search for ways to
induce pluripotency without incurring genetic change has thus
become the focus of intense research effort. Toward this end,
iPSCs have been derived via excisable lentiviral and transposon
vectors or through repeated application of transient plasmid,
episomal, and adenovirus vectors (Chang et al., 2009; Kaji
et al., 2009; Okita et al., 2008; Stadtfeld et al., 2008; Woltjen
et al., 2009; Yu et al., 2009). iPSCs have also been derived
with two DNA-free methods: serial protein transduction with
recombinant proteins incorporating cell-penetrating peptide
moieties (Kim et al., 2009; Zhou et al., 2009) and transgene.
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based reproductive cycle (Fusaki et al., 2009).
Despite such progress, considerable limitations accompany
the nonintegrative iPSC derivation strategies devised thus far.
For example, although DNA transfection-based methodologies
are ostensibly safe, they nonetheless entail some risk of genomic
recombination or insertional mutagenesis. In protein-based
strategies, the recombinant proteins used are challenging to
generate and purify in the quantities required (Zhou et al.,
2009). Use of Sendai virus requires stringent steps to purge
reprogrammed cells of replicating virus, and the sensitivity of
the viral RNA replicase to transgene sequence content may limit
the generality of this reprogramming vehicle (Fusaki et al., 2009).
Importantly, methods that rely on repeat administration of tran-
sient vectors, whether DNA or protein based, have so far shown
very low iPSC derivation efficiencies (Jia et al., 2010; Kim et al.,
2009; Okita et al., 2008; Stadtfeld et al., 2008; Yu et al., 2009;
Zhou et al., 2009), presumably because of weak or inconstant
expression of reprogramming factors.
Herewedemonstrate that repeated administration of synthetic
messenger RNAs incorporating modifications designed to
bypass innate antiviral responses can reprogram differentiated
human cells to pluripotency with conversion efficiencies and
kinetics substantially superior to established viral protocols.
Furthermore, this simple, nonmutagenic, and highly controllable
technology is applicable to a range of tissue-engineering tasks,
exemplified here by RNA-mediated directed differentiation of
RNA-iPSCs (RiPSCs) to terminally differentiated myogenic cells.
RESULTS
Development of Modified RNAs for Directing Cell Fate
We manufactured mRNA by using in vitro transcription (IVT)
reactions templated by PCR amplicons (Figure S1 available on-
line). To promote efficient translation and boost RNA half-life in
the cytoplasm, a 50 guanine cap was incorporated by inclusion
of a synthetic cap analog in the IVT reactions (Yisraeli and
Melton, 1989). Within our IVT templates, the open reading frame
(ORF) of the gene of interest is flanked by a 50 untranslated region
(UTR) containing a strong Kozak translational initiation signal and
an alpha-globin 30 UTR terminating with an oligo(dT) sequence
for templated addition of a polyA tail.
Cytosolic delivery of mRNA into mammalian cells can be
achieved via electroporation or by complexing the RNA with
a cationic vehicle to facilitate uptake by endocytosis (Audouy
and Hoekstra, 2001; Elango et al., 2005; Holtkamp et al., 2006;
Van den Bosch et al., 2006; Van Tendeloo et al., 2001). We
focused on the latter approach, reasoning that this would allow
for repeated transfection to sustain ectopic protein expression
over the days to weeks required for cellular reprogramming. In
preliminary experiments in which synthetic RNA encoding GFP
was transfected into murine embryonic fibroblasts and human
epidermal keratinocytes, a high, dose-dependent cytotoxicity
was observed that was not attributable to the cationic vehicle,
which was exacerbated on repeated transfection. These exper-
iments revealed a serious impediment to achieving sustained
protein expression by mRNA transfection and highlighted
a need to develop a technology that would permit sustained
protein expression with mRNA with reduced cellular toxicity.CelIt is known that exogenous single-stranded RNA (ssRNA) acti-
vates antiviral defenses in mammalian cells through interferon-
and NF-kB-dependent pathways (Diebold et al., 2004; Hornung
et al., 2006; Kawai and Akira, 2007; Pichlmair et al., 2006;
Uematsu and Akira, 2007). We sought approaches to reduce
the immunogenic profile of synthetic RNA in order to increase
the sustainability of RNA-mediated protein expression. Cotran-
scriptional capping yields a significant fraction of uncapped
IVT products bearing 50 triphosphates, which can be detected
by the ssRNA sensor RIG-I (Hornung et al., 2006; Pichlmair
et al., 2006), and have also been reported to activate PKR,
a global repressor of protein translation (Nallagatla and Bevilac-
qua, 2008). We therefore treated synthesized RNA with a phos-
phatase, which resulted in modest reductions in cytotoxicity
upon transfection (data not shown).
Eukaryotic mRNA is extensively modified in vivo, and the pres-
ence of modified nucleobases has been shown to reduce
signaling by RIG-I and PKR, as well as by the less widely
expressed but inducible endosomal ssRNA sensors TLR7 and
TLR8 (Kariko´ et al., 2005, 2008; Kariko´ and Weissman, 2007;
Nallagatla and Bevilacqua, 2008; Nallagatla et al., 2008; Uzri
and Gehrke, 2009). In an attempt to further reduce innate
immune responses to transfected RNA, we synthesized mRNAs
incorporating modified ribonucleoside bases. Complete substi-
tution of either 5-methylcytidine (5mC) for cytidine or pseudour-
idine (psi) for uridine in GFP-encoding transcripts markedly
improved viability and increased ectopic protein expression,
although the most significant improvement was seen when
both modifications were used together (Figures 1A–1C). These
modifications dramatically attenuated interferon signaling as
revealed by qRT-PCR for a panel of interferon response genes,
although residual upregulation of some interferon targets was
still detected (Figure 1D). It is known that cellular antiviral
defenses can self-prime through a positive-feedback loop
involving autocrine and paracrine signaling by type I interferons
(Randall and Goodbourn, 2008). Media supplementation with
a recombinant version of B18R protein, a Vaccinia virus decoy
receptor for type I interferons (Symons et al., 1995), further
increased cell viability of RNA transfection in some cell types
(data not shown). Synthesis of RNA with modified ribonucleo-
tides and phosphatase treatment (henceforth, modified RNAs),
used in conjunction with media supplementation with the inter-
feron inhibitor B18R, allowed for high, dose-dependent levels
of protein expression with high cell viability (Figure 1E).
Transfection of modified RNA encoding GFP into six human
cell types showed highly penetrant expression (50%–90% posi-
tive cells), demonstrating the applicability of this technology to
diverse cell types (Figure S2A). Simultaneous delivery of modi-
fied RNAs encoding mCherry and GFP containing a nuclear
localization signal confirmed that generalized coexpression of
multiple proteins could be achieved in mammalian cells and
that expressed proteins could be correctly localized to different
cellular compartments (Figure 1F). Ectopic protein expression
after RNA transfection is transient owing to RNA and protein
degradation and the diluting effect of cell division. To establish
the kinetics and persistence of protein expression, modified
RNA encoding GFP variants designed for high and low protein
stability (Li et al., 1998) were synthesized and transfected into
keratinocytes. Time course analysis by flow cytometry showedl Stem Cell 7, 618–630, November 5, 2010 ª2010 Elsevier Inc. 619
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stability variant but peaked within 12 hr and decayed rapidly
thereafter for the destabilized GFP (Figure S2B). These results
indicated that a repetitive transfection regimen would be
required to sustain high levels of ectopic expression for short-
lived proteins over an extended time course. To address this
and further examine the impact of repeated RNA transfection
on cell growth and viability, we transfected BJ fibroblasts for
10 consecutive days with either unmodified or modified RNAs
encoding a destabilized nuclear GFP and appropriate controls
(Figure S3A). Daily transfection with modified RNA permitted
sustained protein expression without substantially compro-
mising the viability of the culture beyond a modest reduction in
growth kinetics that was largely attributable to the transfection
reagent (Figures 1G and 1H; Figure S2C). Microarray analysis
of the cultures after the tenth and final transfection revealed
that prolonged daily transfection with modified RNA did not
significantly alter the molecular profile of the transfected cells
(Figure S2D), although upregulation of a number of interferon
response genes was noted, consistent with our previous obser-
vation that the RNA modifications did not completely abrogate
interferon signaling (Figure 1D; Figure S2E). By contrast,
repeated transfection with unmodified RNA severely compro-
mised the growth and viability of the culture through elicitation
of a massive interferon response (Figure 1D), indicating that
the use of unmodified RNA was not a viable strategy for
sustaining polypeptide expression in cells (Figure 1G).
To determine whether modified RNAs could be used to
directly alter cell fate, we synthesized modified RNA encoding
the myogenic transcription factor MYOD (Davis et al., 1987)
and transfected it into murine C3H10T1/2 cells over the course
of 3 days, followed by continued culturing in a low serum media
for an additional 3 days. The emergence of large, multinucleated
myotubes that stained positive for the myogenic markers myo-
genin and myosin heavy chain (MyHC) provided proof of prin-
ciple that transfection with modified RNAs could be utilized to
efficiently direct cell fate (Figure 1I).
Generation of Induced Pluripotent Stem Cells via
Modified RNAs
We next sought to determine whether induced pluripotent stem
cells (iPSCs) could be derived via modified RNAs. To this end,
modified RNAs encoding the four canonical Yamanaka factors,
KLF4 (K), c-MYC (M),OCT4 (O), and SOX2 (S), were synthesized
and transfected into cells. Immunostaining with antibodiesFigure 1. Modified RNA Overcomes Antiviral Responses and Can Be U
(A) Microscopy images showing keratinocytes transfected 24 hr earlier with 400
pseudouridine modified (Psi), or 5mC + Psi modified RNA encoding GFP.
(B and C) Percent viability (B) and mean fluorescence intensity (C) of the cells sh
(D) Quantitative RT-PCR data showing expression of six interferon-regulated gen
fied (5mC + Psi) RNA encoding GFP (1200 ng/well), and vehicle and untransfect
(E) Flow cytometry histograms showing GFP expression in keratinocytes transfe
(F) Microscopy images of keratinocytes cotransfected with modified RNAs enco
(G) Growth kinetics of BJ fibroblasts transfected daily with unmodified ormodified
fected controls for 10 days.
(H) SustainedGFP expression of modified RNA-transfected cells described in (G) a
(left) and flow cytometry (right).
(I) Immunostaining for the muscle-specific proteins myogenin and myosin heavy c
daily transfections with a modified RNA encoding MYOD.
Error bars indicate SD, n = 3 for all panels. See also Figure S2.
Celdirected against OCT4, KLF4, and SOX2 demonstrated that
each of the factors was robustly expressed and correctly local-
ized to the nucleus (Figure 2A). Expression kinetics was moni-
tored by flow cytometry, which showed maximal protein expres-
sion 12 to 18 hours after transfection, followed by rapid turnover
of these transcription factors (Figure 2B). From this we
concluded that daily transfections would be required to maintain
high levels of expression of the Yamanaka factors during long-
term, multifactor reprogramming regimens.
We next sought to establish a protocol to ensure sustained,
high-level protein expression through daily transfection of modi-
fied RNAs by exploring a matrix of conditions encompassing
different transfection reagents, culture media, feeder cell types,
and RNA doses (data not shown). Once optimized, we initiated
long-term reprogramming experiments with human ESC-derived
dH1f fibroblasts, which display relatively efficient viral-mediated
iPSC conversion (Chan et al., 2009; Park et al., 2008). Low-
oxygen (5% O2) culture conditions and a KMOS stoichiometry
of 1:1:3:1 were employed, because these have been reported
to promote efficient iPSC conversion (Kawamura et al., 2009;
Papapetrou et al., 2009; Utikal et al., 2009; Yoshida et al.,
2009). Modified RNA encoding a destabilized nuclear GFP was
spiked into the KMOS RNA cocktail to allow visualization of
continued protein expression throughout the experimental
time course (Figure S3A). Widespread transformation of fibro-
blast morphology to a compact, epithelioid morphology was
observed within the first week of modified RNA transfection,
followed by emergence of canonical hESC-like colonies with
tight morphology, well-defined borders, and prominent nucleoli
toward the end of the second week of transfection (Figure 2C).
RNA transfection was terminated on day 17, and colonies were
mechanically picked 3 days later, which were then expanded
under standard ESC culture conditions to establish 14 prospec-
tive iPSC lines, designated dH1f-RiPSC (RNA-derived iPSC)
1–14.
We next attempted to reprogram somatically derived cells to
pluripotency by using a similar reprogramming regimen. Antici-
pating that these cells might be more challenging to reprogram,
we employed a five-factor cocktail including a modified RNA
encoding LIN28 (KMOSL), which has been shown to facilitate
reprogramming (Yu et al., 2007; Hanna et al., 2009), and we
supplemented the media with valproic acid (VPA), a histone
deacetylase inhibitor that has been reported to increase reprog-
ramming efficiency (Huangfu et al., 2008). Four human cell types
were tested: Detroit 551 (D551) and MRC-5 fetal fibroblasts, BJsed to Direct Cell Fate
ng/well of synthetic unmodified (No Mods), 5-methyl-cytosine modified (5mC),
own in (A) as measured by flow cytometry.
es in BJ fibroblasts 24 hr after transfection with unmodified (No Mods) or modi-
ed controls.
cted with 0–160 ng of modified-RNA, 24 hr posttransfection.
ding GFP with a nuclear localization signal, and mCherry (cytosolic) proteins.
RNAs encoding a destabilized nuclear-localized GFP, and vehicle and untrans-
t day 10 of transfection shown by fluorescence imaging with bright field overlay
hain (MyHC) in murine C3H/10T1/2 cell cultures 3 days after three consecutive
l Stem Cell 7, 618–630, November 5, 2010 ª2010 Elsevier Inc. 621
Figure 2. Generation of RNA-Induced Pluripotent Stem Cells
(A) Immunostaining for human KLF4, OCT4, and SOX2 proteins in keratinocytes 15 hr posttransfection with modified RNA encoding KLF4, OCT4, or SOX2.
(B) Time course showing kinetics and stability of KLF4, OCT4, and SOX2 proteins after modified RNA transfection, assayed by flow cytometry after intracellular
staining of each protein.
(C) Bright-field images taken during the derivation of RNA-iPSCs (RiPS) from dH1f fibroblasts showing early epitheliod morphology (day 6), small hESC-like colo-
nies (day 17), and appearance of mature iPSC clones after mechanical picking and expansion (day 24).
(D) Immunohistochemistry showing expression of a panel of pluripotency markers in expanded RiPSC clones derived from dH1f fibroblasts, Detroit 551 (D551)
and MRC-5 fetal fibroblasts, BJ postnatal fibroblasts, and cells derived from a skin biopsy taken from an adult cystic fibrosis patient (CF), shown also in high
magnification. BG01 hESCs and BJ1 fibroblasts are included as positive and negative controls, respectively. Scale bars represent 200 mm.
See also Figures S3 and S4.
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a primary skin biopsy taken from an adult cystic fibrosis patient
(CF cells). Daily transfection with the modified RNA KMOSL
cocktail gave rise to numerous hESC-like colonies in the D551,
BJ, CF, and MRC5 cultures that were mechanically picked at
day 18, 20, 21, and 25, respectively. More than 10 RiPSC clones
were expanded for each of the somatic lines, with notably very
few clones failing to establish. Immunostaining confirmed the
expression of OCT4, NANOG, TRA-1-60, TRA-1-81, SSEA3,
and SSEA4 in all the RiPSC lines examined (Figure 2D;
Figure S3B). DNA fingerprinting confirmed parental origin of
three RiPSC clones from each somatic cell derivation, and all
clones presented normal karyotypes (data not shown). Of note,
additional experiments conducted in the presence or absence
of VPA showed little difference in reprogramming efficiency
(data not shown), and VPAwas therefore not used in subsequent
experiments.
Molecular Characterization and Functional Potential
of RiPSCs
A number of molecular and functional assays were performed to
further assess whether the RiPSCs had been reprogrammed to
pluripotency (Table S1). Multiple RiPSC lines derived from
each of the five starting cell types were evaluated by quantitative
RT-PCR (qRT-PCR), and all demonstrated robust expression of
the pluripotency-associated transcripts OCT4, SOX2, NANOG,
and hTERT (Figure 3A). Bisulfite sequencing of the Oct4 locus
revealed extensive demethylation relative to the parental fibro-
blasts, an epigenetic state equivalent to human ESCs
(Figure 3B).
To gain more global insight into the molecular properties of
RiPSCs, gene expression profiles of RiPSC clones from multiple
independent derivations were generated and compared to fibro-
blasts, human ESCs, and virally derived iPSC lines. These anal-
yses revealed that all modified RNA-derived iPSC clones exam-
ined had a molecular signature that very closely recapitulated
that of human ESCs while being highly divergent from the profile
of the parental fibroblasts (Figure 3C). Importantly, pluripotency-
associated transcripts including SOX2, REX1, NANOG, OCT4,
LIN28, and DNMT3B were substantially upregulated in the
RiPSCs compared to the parental fibroblast lines to levels
comparable to hESCs (Figure 3C). Furthermore, when the tran-
scriptional profiles were subjected to unsupervised hierarchical
clustering analysis, all RiPSC clones analyzed clustered more
closely to hESC than did virally derived iPSCs, suggesting that
modified RNA-derived iPSCsmore fully recapitulated themolec-
ular signature of human ESCs (Figure 3D).
To test the developmental potential of RiPSCs, embryoid
bodies (EBs) were generated frommultiple clones from five inde-
pendent RiPSC derivations, and beating cardiomyocytes were
observed for the vast majority of the EBs (Table S1, Movie S1).
Mesodermal potential was further evaluated in methylcellulose
blood-forming assays that showed that all lines tested were
robustly able to differentiate into hematopoietic precursors
capable of giving rise to colony numbers and a spectrum of
blood colony types comparable to human ESCs (Figure 4A;
Table S1). A subset of clones was further plated onto
matrigel and differentiated into Tuj1-positive neurons (ectoderm)
and alpha-fetoprotein-positive endodermal cells (Figure 4B;CelTable S1). Finally, trilineage differentiation potential was
confirmed in vivo by the formation of teratomas from dH1F-,
CF-, and BJ-RiPSCs, which histologically revealed cell types of
the three germ layers (Figure 4C; Figure S5, Table S1).
Taken together, these data demonstrate by the most stringent
criteria available to human pluripotent cells (Chan et al., 2009;
Smith et al., 2009) that modified RNA-derived iPSC clones
from multiple independent derivations were reprogrammed to
pluripotency and closely recapitulated the functional and molec-
ular properties of human ESCs.
Modified RNAs Generate iPSCs at Very High Efficiency
During the course of our experiments, we noted surprisingly high
reprogramming efficiencies and rapid kinetics with which
RiPSCs were generated. To quantify this more thoroughly,
a number of reprogramming experiments were undertaken in
which quantitative readout of efficiency was based on colony
morphology and expression of the stringent pluripotency
markers TRA-1-60 and TRA-1-81 (Chan et al., 2009; Lowry
et al., 2008). In one set of experiments, BJ fibroblasts transfected
with a five-factor modified RNA cocktail (KMOSL) demonstrated
an iPSC conversion efficiency of more than 2%, regardless of
whether the cells were passaged in the presence or absence
of Rho-associated kinase (ROCK), Y-27632 (Figures 5A and
5B; Table 1). This efficiency was two orders of magnitude higher
than those typically reported for virus-based derivations. More-
over, in contrast to virus-mediated BJ-iPSC derivations, in which
iPSC colonies typically take around 4 weeks to emerge, by day
17 of RNA transfection the plates had already become over-
grown with ESC-like colonies (Figure 5A).
We next evaluated the contributions of low-oxygen culture and
LIN28 to the efficiency of RiPSC derivation. The yield of TRA-1-
60/TRA-1-81-positive colonies in the ambient (20%) oxygen
condition was 4-fold lower than in the cultures maintained at
5% O2 when using KMOS RNA, but this deficit was negated
when LIN28 was added to the cocktail (Figures 5C and 5D;
Table 1). The highest conversion efficiency (4.4%) was observed
when low-oxygen culture and the five-factor KMOSL cocktail
were combined.
To directly compare the kinetics and efficiency of our RiPSC
derivation protocol against an established viral protocol, we con-
ducted an experiment in which dH1f fibroblasts were transfected
with either KMOS-modified RNAs or transduced with KMOS
retroviruses in parallel. As had been observed in previous exper-
iments, ESC-like colonies began to emerge toward the end of the
second week on the RNA-transfected cultures, and the plates
became overgrown with ESC-like colonies by the 16th and final
day of transfection. By contrast, no ESC-like colonies had
appeared in the retrovirally transduced cultures by this time
point, and colonies began to emerge only on the 24th day post-
transduction, a time point consistent with previous reports
describing iPSC derivation by retroviruses (Lowry et al., 2008;
Takahashi et al., 2007). The retroviral cultures were fixed for
analysis on day 32. Both arms of the experiment were then
immunostained for TRA-1-60 and colonies were counted. iPSC
derivation efficiencies were 1.4% and 0.04% for modified RNA
and retrovirus, respectively, corresponding to 36-fold higher
conversion efficiency with the modified RNA protocol (Figures
5E and 5F; Table 1). These experiments also revealed that thel Stem Cell 7, 618–630, November 5, 2010 ª2010 Elsevier Inc. 623
Figure 3. Molecular Characterization of RiPSCs
(A) Heatmap showing results of qRT-PCR analysis measuring the expression of pluripotency-associated genes in RiPSC lines, parental fibroblasts, and viral-
derived iPSCs relative to hESC controls.
(B) Heatmap showing results of OCT4 promoter methylation analysis of RiPSC lines, parental fibroblasts, and hESC controls.
(C) Global gene expression profiles of BJ-, MRC5-, and dH1F-derived RiPSCs shown in scatter plots against parental fibroblasts and hESCs with pluripotency-
associated transcripts indicated.
(D) Dendrogram showing unsupervised hierarchical clustering of the global expression profiles for RiPSCs, parental fibroblasts, hESCs, and virus-derived iPSCs.
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fast as retroviral iPSC derivation. Thus, by the combined criteria
of colony numbers and kinetics of reprogramming, the efficiency
of modified RNA iPSC derivation greatly exceeds that of conven-
tional retroviral approaches.
It should be noted that in the experiments described above,
transfected fibroblast cultures were passaged once at an early
time point (day 6 or 7) in order to promote fibroblast proliferation,
which has been shown to facilitate reprogramming (Hanna et al.,
2009). However, in preliminary experiments, RiPSCs were also
efficiently derived from BJ and Detroit 551 fibroblasts in the
absence of cell passaging, indicating that splitting the culture624 Cell Stem Cell 7, 618–630, November 5, 2010 ª2010 Elsevier Incduring the reprogramming processwas not required for modified
RNA iPSC derivation (Figure S4, and data not shown).
Utilization of Modified RNA to Direct Differentiation
of Pluripotent RiPSCs to a Terminally Differentiated
Cell Fate
To realize the promise of iPSC technology for regenerative medi-
cine or disease modeling, it is imperative that the multilineage
differentiation potential of pluripotent cells be harnessed.
Although progress has been made in directing the differentiation
of pluripotent ESCs to various lineages by modulating the extra-
cellular cytokine milieu, such protocols remain relatively.
Figure 4. Trilineage Differentiation of RiPSCs
(A) Yield and typology of blood-lineage colonies produced
by directed differentiation of embryoid bodies in methyl-
cellulose assays with RiPSC clones derived from BJ,
CF, D551, and MCR5 fibroblasts, and a human ESC (H1)
control.
(B) Immunostaining showing expression of the lineage
markers Tuj1 (neuronal, ectodermal) and alpha-fetopro-
tein (epithelial, endodermal) in RiPSC clones from three
independent RiPSC derivations subjected to directed
differentiation.
(C) Hematoxylin and eosin staining of BJ-, CF-, and dH1F-
RiPSC-derived teratomas showing histological overview,
ectoderm (pigmented epithelia [BJ and CF], neural
rosettes [dH1F]), mesoderm (cartilage, all), and endoderm
(gut-like endothelium, all). For blood formation and
methylcellulose assays, n = 3 for each clone.
See also Figure S5.
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fied RNAs, we reasoned that this technology might also be
utilized to redirect pluripotent cells toward differentiated cell
fates. To test this hypothesis, we subjected one of our validated
RiPSC lines to a simple in vitro differentiation protocol in which
FGF was withdrawn, serum added, and the cells plated onto
gelatin (Figure 6). Cells obtained under these conditions were
then subjected to three consecutive days of transfection with
a MYOD-encoding modified RNA followed by an additional
3 days of culture in low serum conditions. The cultures were
then fixed and immunostained for themyogenicmarkersmyoge-
nin and MyHC, which revealed a high percentage of large multi-
nucleated myogenin and MyHC double-positive myotubes
(Figure 6).
Taken together, these experiments provide proof of principle
that modified RNAs can be used to both efficiently reprogram
cells to a pluripotent state and direct the fate of such cells to
a terminally differentiated somatic cell type.Cell Stem Cell 7, 618DISCUSSION
By using a combination of RNA modifications
and a soluble interferon inhibitor to overcome
innate antiviral responses, we have developed
a technology that enables highly efficient re-
programming of somatic cells to pluripotency
and can also be harnessed to direct the differ-
entiation of pluripotent cells toward a desired
lineage. Although it is relatively technically
complex, the methodology described here
offers several key advantages over established
reprogramming techniques. By obviating the
need to perform experiments under the strin-
gent biological containment required for virus-
based approaches, modified RNA technology
should make reprogramming accessible to
a wider community of researchers. More funda-
mentally, because our technology is RNA
based, it completely eliminates the risk of
genomic integration and insertional mutagen-
esis inherent to all DNA-based methodologies,including those that are ostensibly nonintegrating. Moreover,
our approach allows protein stoichiometry to be exquisitely
regulated within cultures while avoiding the stochastic variation
of expression typical of integrating vectors, as well as the uncon-
trollable effects of viral silencing. Given the stepwise character of
the phenotypic changes observed during pluripotency induction
(Chan et al., 2009; Smith et al., 2010), it seems likely that indi-
vidual transcription factors play distinct, stage-specific roles
during reprogramming. The unprecedented potential for
temporal control over individual factor expression afforded by
our technology should help researchers unravel these nuances,
yielding insights that can be applied to further enhance the effi-
ciency and kinetics of reprogramming.
The risk of mutagenesis is not the only safety concern holding
back clinical application of induced pluripotency, and it has
become increasingly apparent that all iPSCs are not created
equal with respect to epigenetic landscape and developmental
plasticity (Hu et al., 2010; Miura et al., 2009). In this regard, we–630, November 5, 2010 ª2010 Elsevier Inc. 625
Figure 5. Pluripotency Induction by Modi-
fied RNAs Is Highly Efficient
(A and B) TRA-1-60 horseradish peroxidase (HRP)
staining conducted at day 18 of a BJ-RiPSC deri-
vation with modified RNAs encoding KMOSL (A)
and frequency of TRA-1-60-positive colonies
produced in the experiment relative to number of
cells initially seeded (B). Error bars show SD,
n = 6 for each condition.
(C and D) TRA-181 HRP, TRA-160 immunofluo-
rescence, and Hoechst staining (C) and colony
frequencies for dH1f-RiPS experiments done
with 4-factor (KMOS) and 5-factor (KMOSL) modi-
fied RNA cocktails under 5% O2 or ambient
oxygen culture conditions quantified at day 18
(D). Control wells were transfected with equal
doses of modified RNA encoding GFP.
(E) Kinetics and efficiency of retroviral and modi-
fied RNA reprogramming. Timeline of colony
formation (top), TRA-1-60 HRP immunostaining
(bottom left), and TRA-1-60-positive colony
counts (bottom right) of dH1f cells reprogrammed
with KMOS retroviruses (MOI = 5 of each) or modi-
fied RNA KMOS cocktails (n = 3 for each condi-
tion).
See also Figure S4.
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Directing Cell Fate with Modified mRNAhave applied the most stringent molecular and functional criteria
for reprogramming human cells to pluripotency (Chan et al.,
2009; Smith et al., 2009). Our results demonstrate that modified
RNA-derived iPSC clones frommultiple independent derivations
were fully reprogrammed to pluripotency and that the resulting
cells very closely recapitulated the functional and molecular
properties of human ESCs. Our observation that modified
RNA-derived iPSCs more faithfully recapitulated the global tran-
scriptional signature of human ESCs than retrovirally derived
iPSCs is important because it suggests that RNA reprogramming
may produce higher-quality iPSCs, possibly owing to the fact
that they are transgene free.
The transient and nonmutagenic character of RNA-based
protein expression could also deliver important clinical benefits
outside the domain of lineage reprogramming. Indeed, the use
of RNA transfection to express cancer or pathogen antigens
for immunotherapy is already an active research area (Rabino-
vich et al., 2006, 2008; Van den Bosch et al., 2006; Weissman
et al., 2000), and such approaches may benefit from the nonim-
munogenic properties of modified RNAs. One can readily
envisage employingmodified RNA to transiently express surface
proteins such as homing receptors to target cellular therapies
toward specific organs, tissues, or diseased cells.
For tissue engineering to progress further into the clinic, there
is a pressing need for safe and efficient means to redirect cell
fate. This is doubly apparent when one considers that iPSCs
are only a starting point for patient-specific therapies, and spec-626 Cell Stem Cell 7, 618–630, November 5, 2010 ª2010 Elsevier Inc.ification of clinically useful cell types is
still required to produce autologous
tissues for transplantation or for disease
modeling. Importantly, we have demon-
strated that our modified RNA-based
technology enables highly efficientreprogramming and that it can equally be applied to efficiently
redirect pluripotent cell fate to terminally differentiated fates
without compromising genomic integrity. In light of these consid-
erations, we believe that our approach has the potential to
become a major enabling technology for cell-based therapies
and regenerative medicine.
EXPERIMENTAL PROCEDURES
Construction of IVT Templates
The pipeline for production of IVT template constructs and subsequent RNA
synthesis is schematized in Figure S1. The oligonucleotide sequences used
in the construction of IVT templates are shown in Table S2. All oligos were
synthesized by Integrated DNA Technologies (Coralville, IA). ORF PCRs
were templated from plasmids bearing human KLF4, c-MYC, OCT4, SOX2,
human ESC cDNA (LIN28), Clontech pIRES-eGFP (eGFP), pRVGP (d2eGFP),
and CMV-MyoD from Addgene. The ORF of the low-stability nuclear GFP
was constructed by combining the d2eGFP ORF with a 30 nuclear localization
sequence. PCR reactions were performed with HiFi Hotstart (KAPA Biosys-
tems, Woburn, MA) per the manufacturer’s instructions. Splint-mediated liga-
tions were carried out with Ampligase Thermostable DNA Ligase (Epicenter
Biotechnologies, Madison, WI). UTR ligations were conducted in the presence
of 200 nM UTR oligos and 100 nM splint oligos, with 5 cycles of the following
annealing profile: 95C for 10 s; 45C for 1 min; 50C for 1 min; 55C for 1 min;
60C for 1 min. A phosphorylated forward primer was employed in the ORF
PCRs to facilitate ligation of the top strand to the 50 UTR fragment. The 30
UTR fragment was also 50-phosphorylated via polynucleotide kinase (New
England Biolabs, Ipswich, MA). All intermediate PCR and ligation products
were purified with QIAquick spin columns (QIAGEN, Valencia, CA) before
further processing. Template PCR amplicons were subcloned with the pcDNA
Table 1. Quantification of Reprogramming Efficiency
Experiment Cells Plated Split Condition Well Fraction Colonies/Well Efficiency (%)
BJ (KMOSL) 300,000 d7 Y27632- 1/24 249 ± 21 2.0
Y27632+ 1/24 326 ± 49 2.6
4-Factor (KMOS) versus
5-Factor (KMOSL)
50,000 d6 4F 20% O2 1/6 48 ± 18 0.6
4F 5% O2 1/6 228 ± 30 2.7
5F 20% O2 1/6 243 ± 42 2.9
5F 5% O2 1/6 367 ± 38 4.4
RNA versus Virus (KMOS) 100,000 d6 virus 1/3 13 ± 3.5 0.04
RNA 1/6 229 ± 39 1.4
For each experimental condition, efficiency was calculated by dividing the average count of TRA-1-60-positive colonies per well by the initial number of
cells plated, scaled to the fraction of cells replated in each well. Cultures were passaged at day 6 or 7 as indicated. The BJ experiment was started in
a 10 cm dish; dH1f trials in individual wells of a 6-well plate. Colony counts are shown ± SD, n = 6, except in the RNA versus Virus trial, where n = 9 for
virus, n = 18 for RNA.
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Directing Cell Fate with Modified mRNA3.3-TOPO TA cloning kit (Invitrogen, Carlsbad, CA). Plasmid inserts were
excised by restriction digest and recovered with SizeSelect gels (Invitrogen)
before being used to template tail PCRs.Synthesis of Modified RNA
RNA was synthesized with the MEGAscript T7 kit (Ambion, Austin, TX), with
1.6 mg of purified tail PCR product to template each 40 mL reaction. A custom
ribonucleoside blend was used comprising 30-0-Me-m7G(50 )ppp(50)G ARCA
cap analog (New England Biolabs), adenosine triphosphate and guanosine
triphosphate (USB, Cleveland, OH), 5-methylcytidine triphosphate and pseu-
douridine triphosphate (TriLink Biotechnologies, San Diego, CA). Final nucleo-
tide reaction concentrations were 6 mM for the cap analog, 1.5 mM for guano-
sine triphosphate, and 7.5 mM for the other nucleotides. Reactions were
incubated 3–6 hr at 37C and DNase treated as directed by the manufacturer.
RNA was purified with Ambion MEGAclear spin columns, then treated with
Antarctic Phosphatase (New England Biolabs) for 30 min at 37C to remove
residual 50-triphosphates. Treated RNA was repurified, quantitated by Nano-
drop (Thermo Scientific, Waltham, MA), and adjusted to 100 ng/mL working
concentration by addition of Tris-EDTA (pH 7.0). RNA reprogramming cock-
tails were prepared by pooling individual 100 ng/mL RNA stocks to produce
a 100 ng/mL (total) blend. The KMOS[L]+GFP cocktails were formulated to
give equal molarity for each component except for OCT4, which was includedCelat 33molar concentration. Volumetric ratios used for pooling were as follows:
170:160:420:130:120[:90] (KLF4:c-MYC:OCT4:SOX2:GFP[:LIN28]).
Cells
Primary human neonatal epidermal keratinocytes, BJ human neonatal foreskin
fibroblasts, MRC-5 human fetal lung fibroblasts, and Detroit 551 human fetal
skin fibroblasts were obtained from ATCC (Manassas, VA). CF cells were ob-
tained with informed consent from a skin biopsy taken from an adult cystic
fibrosis patient. dH1f fibroblasts were subcloned from fibroblasts produced
by directed differentiation of the H1-OGN human ESC line as previously
described (Park et al., 2008). BGO1 hESCs were obtained from BresaGen
(Athens, GA). H1 and H9 hESCs were obtained from WiCell (Madison, Wi).
RNA Transfection
RNA transfections were carried out with RNAiMAX (Invitrogen) or TransIT-
mRNA (Mirus Bio, Madison, WI) cationic lipid delivery vehicles. RNAiMAX
was used for RiPSC derivations, the RiPSC-to-myogenic conversion, and for
the multiple cell type transfection experiment documented in Figure S2.
All other transfections were performed with TransIT-mRNA. For RNAiMAX
transfections, RNA and reagent were first diluted in Opti-MEM basal media
(Invitrogen). 100 ng/mL RNA was diluted 53 and 5 mL of RNAiMAX per micro-
gram of RNA was diluted 103, then these components were pooled and incu-
bated 15 min at room temperature (RT) before being dispensed to cultureFigure 6. Efficient Directed Differentiation of
RiPSCs to Terminally Differentiated Myogenic
Fate via Modified RNA
(A) Schematic of experimental design.
(B) Bright-field and immunostained images showing large,
multinucleated, myosin heavy chain (MyHC) and myoge-
nin-positive myotubes in cells fixed 3 days after cessation
of MYOD modified RNA transfection. Modified RNA en-
coding GFP was administered to the controls.
(C) Penetrance of myogenic conversion relative to daily
RNA dose. Black bars refer to an experiment in which
cultures were plated at 104 cells/cm2, gray bars to cultures
plated at 5 3 103 cells/cm2. Error bars show SD for tripli-
cate wells.
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Opti-MEM and BOOST reagent was added (2 mL per microgram of RNA),
then TransIT-mRNA was added (2 mL per microgram of RNA), and the RNA-
lipid complexes were delivered to culture media after a 2 min incubation at
RT. RNA transfections were performed in Nutristem xeno-free hESC media
(Stemgent, Cambridge, MA) for RiPSC derivations, Dermal Cell Basal Medium
plus Keratinocyte Growth Kit (ATCC) for keratinocyte experiments, and Opti-
MEM plus 2% FBS for all other experiments described. The B18R interferon
inhibitor (eBioscience, San Diego, CA) was used as a media supplement at
200 ng/mL.
qRT-PCR
Transfected cells were lysed with 400 mL CellsDirect reagents (Invitrogen), and
20 mL of each lysatewas taken forward to a 50 mL reverse transcription reaction
via the VILO cDNA synthesis kit (Invitrogen). Reactions were purified on QIA-
quick columns (QIAGEN). qRT-PCR reactions were performed with SYBR
FAST qPCR supermix (KAPA Biosystems).
Reprogramming to Pluripotency
Gamma-irradiated human neonatal fibroblast feeders (GlobalStem, Rockville,
MD) were seeded at 33,000 cells/cm2. Nutristem media was replaced daily,
4 hr after transfection, and supplemented with 100 ng/mL bFGF and
200 ng/mL B18R (eBioscience, San Diego, CA). Where applied, VPA was
added to media at 1 mM final concentration on days 8–15 of reprogramming.
Low-oxygen experiments were carried out in a NAPCO 8000 WJ incubator
(Thermo Scientific). Media were equilibrated at 5% O2 for approximately 4 hr
before use. Cultures were passaged with TrypLE Select recombinant protease
(Invitrogen). Y27632 ROCK inhibitor (Watanabe et al., 2007) was used at 10 mM
in recipient plates until the next media change. The daily RNA dose applied in
the RiPSC derivations was 1200 ng per well (6-well plate format) or 8 mg to
a 10 cm dish.
For RNA versus retrovirus experiments, starting cultures were seeded with
100,000 cells in individual wells of a 6-well plate via fibroblast media
(DMEM+10% FBS). The next day (day 1), KMOS RNA transfections were initi-
ated in the RNA plate, and the viral plate was transduced with a KMOS retro-
viral cocktail (MOI = 5 for each virus). All wells were passaged on day 6, with
split ratios of 1:6 for the RNA wells and 1:3 for the virus wells. The conditions
applied in the RNA arm of the trial were as in the initial RiPSC derivation,
including the use of Nutristem supplemented with 100 ng/mL bFGF, 5% O2
culture, and human fibroblast feeders. Ambient oxygen tension and other
conventional iPSC derivation conditions were used in the viral arm, the cells
being grown in fibroblast media without feeders until the day 6 split, then being
replated onto CF1 MEF feeders (GlobalStem) with a switch to hESC media
based on Knockout Serum Replacement (Invitrogen) supplemented with
10 ng/mL bFGF.
RiPSC Culturing
RiPSC colonies were mechanically picked and transferred to MEF-coated 24-
well plates with standard hESC medium containing 5 mM Y27632 (BioMol,
Plymouth Meeting, PA). The hESC media comprised DMEM/F12 supple-
mented with 20% Knockout Serum Replacement (Invitrogen), 10 ng/mL of
bFGF (Gembio, West Sacramento, CA), 13 nonessential amino acids (Invitro-
gen), 0.1 mM b-ME (Sigma), 1 mM L-glutamine (Invitrogen), plus antibiotics.
Clones were mechanically passaged once more to MEF-coated 6-well plates,
and then expanded via enzymatic passaging with collagenase IV (Invitrogen).
For RNA and DNA preparation, cells were plated onto hESC-qualified
Matrigel (BD Biosciences) in mTeSR (Stem Cell Technologies, Vancouver,
BC) and further expanded by enzymatic passaging with dispase (Stem Cell
Technologies).
Immunostaining
Cells were fixed in 4% paraformaldehyde for 20 min. Washed cells were
treated with 0.2% Triton X (Sigma) in PBS for 30 min. Cells were blocked
with 3% BSA (Invitrogen) and 5% donkey serum (Sigma) for 2 hr at RT. Cells
were stained in blocking buffer with primary antibodies at 4C overnight. Cells
were washed and stained with secondary antibodies and 1 mg/mL Hoechst
33342 (Invitrogen) in blocking buffer for 3 hr at 4C or for 1 hr at RT, protected
from light. Antibodies were used, at 1:100 dilution: TRA-1-60-Alexa Fluor 647,628 Cell Stem Cell 7, 618–630, November 5, 2010 ª2010 Elsevier IncTRA-1-81-Alexa Fluor 488, SSEA-4-Alexa Fluor 647, and SSEA-3-Alexa 488
(BD Biosciences). Primary OCT4 and NANOG antibodies (Abcam, Cambridge,
MA) were used at 0.5 mg/mL, and an anti-rabbit IgG Alexa Fluor 555 (Invitrogen)
was used as the secondary. Images were acquired with a Pathway 435 bioim-
ager (BD Biosciences). Live imaging was performed as described previously
(Chan et al., 2009). For pluripotency factor time course experiments, trans-
fected human keratinocytes were trypsinized, washed with PBS, and fixed in
4% paraformaldehyde for 10 min. Fixed cells were washed with 0.1 M glycine,
then blocked and permeabilized in PBS/0.5% saponin/1% goat serum (Rock-
land Immunochemicals, Gilbertsville, PA) for 20 min. Cells were incubated for
1 hr at RT with 1:100 diluted primary antibodies for KLF4, OCT4, and SOX2
(Stemgent), washed, then for 45 min at RT with 1:200-diluted DyLight 488-
labeled secondary antibodies (goat anti-mouse IgG+IgM and goat anti-rabbit
IgG). Cells were suspended in PBS and analyzed by flow cytometry.
Gene Expression Analysis
RNA was isolated with the RNeasy kit (QIAGEN) according to the manufac-
turer’s instructions. First-strand cDNA was primed with oligo(dT) primers
and qPCR was performed with primer sets as described previously
(Park et al., 2008), with Brilliant SYBR Green master mix (Stratagene, La
Jolla, CA). For the microarray analysis, RNA probes were prepared and hybrid-
ized toHumanGenomeU133 Plus 2.0 oligonucleotide microarrays (Affymetrix,
Santa Clara, CA) per the manufacturer’s instructions. Arrays were processed
by the Coriell Institute Genotyping and Microarray Center (Camden, NJ).
Gene expression levels were normalized with the Robust Multichip Average
(RMA) algorithm. Hierarchical clustering was performed by means of the
Euclidean distance with average linkage method. The similarity metric for
comparison between different cell lines is indicated on the height of cluster
dendrogram.
Bisulfite Sequencing
DNAwas extracted with the DNeasy Blood and Tissue kit (QIAGEN) according
to the manufacturer’s protocol. Bisulfite treatment of genomic DNA was
carried out with EZ DNAMethylation Kit (ZymoResearch, Orange, CA) accord-
ing to the manufacturer’s protocol. For pyrosequencing analysis, the bisulfate-
treated DNA was first amplified by HotStar Taq Polymerase (QIAGEN) for
45 cycles of (95C 30 s; 53C 30 s; 72C 30 s). The analysis was performed
by EpigenDx with the PSQ96HS system according to standard procedures
with primers that were developed by EpigenDx for the CpG sites at positions
(50) to (+96) from the start codon of the OCT4 gene.
Trilineage Differentiation
Embryoid body (EB) hematopoietic differentiation was performed as previ-
ously described (Chadwick et al., 2003). In brief, RiPSCs and hESC controls
were passaged with collagenase IV and transferred (3:1) in differentiation
medium to 6-well low-attachment plates and placed on a shaker in a 37C
incubator overnight. Starting the next day, media was supplemented with
the following hematopoietic cytokines: 10 ng/mL of interleukin-3 (R&D
Systems, Minneapolis, MN) and interleukin-6 (R&D), 50 ng/mL of G-CSF (Am-
gen, Thousand Oaks, CA) and BMP-4 (R&D), and 300 ng/mL of SCF (Amgen)
and Flt-3 (R&D). Media was changed every 3 days. On day 14 of differentiation,
EBs were dissociated with collagenase B (Roche, Indianapolis, IN). 2 3 104
differentiated cells were plated intomethylcelluloseH4434 (StemCell Technol-
ogies) and transferred with a blunt needle onto 35 mm dishes (Stem Cell Tech-
nologies) in triplicate and incubated at 37C and 5% CO2 for 14 days. Colony
forming units (CFUs) were scored based on morphological characteristics.
For neuronal differentiation, cells were differentiated at 70% confluency as
a monolayer in neuronal differentiation medium (DMEM/F12, Glutamax 1%,
B27-Supplement 1%, N2-Supplement 2%, P/S 1%, and noggin 20 ng/ml).
After 7 days, neuronal structures were visible. For endoderm differentiation
(AFP stain), cells were differentiated as a monolayer in endoderm differentia-
tion medium (DMEM, B27(-RA), and 100 ng/ml activin-a) for 7 days, then
switched to growth medium (DMEM, 10% FBS, 1% P/S) and continued differ-
entiation for 7 days. Antibodies used were as follows: anti-b-Tubulin III (Tuj1)
rabbit anti-human (Sigma, St. Louis, MO), 1:500; AFP (h-140) rabbit polyclonal
IgG (Santa Cruz Biotechnology, Santa Cruz, CA), 1:100 dilution. Secondary
antibodies were conjugated to Alexa Fluor 488 or Alexa Fluor 594..
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Directing Cell Fate with Modified mRNAFor cardiomyocyte differentiation, colonies were digested at 70%
confluency with dispase and placed in suspension culture for embryoid
body (EB) formation in differentiation medium (DMEM, 15% FBS, 100 mM as-
corbic acid). After 11 days, EBs were plated to adherent conditions via gelatin
and the same medium. Beating cardiomyocytes were observed 3 days after
replating.
For teratomas, 2.5 3 106 cells were spun down, and all excess media was
removed. In 20-week-old female SCID mice, the capsule of the right kidney
was gently elevated, and one droplet of concentrated cells was inserted under
the capsule. Tumors harvested at 6–12 weeks were fixed in 4% PFA, run
through an ethanol gradient, and stored in 70% ethanol. Specimens were
sectioned and stained with H&E.
Myogenic Differentiation of RiPSCs
Validated RiPSCs were plated into wells coated with 0.1% gelatin (Millipore,
Billerica, MA) and cultured in DMEM+10% FBS for 4 weeks with passaging
every 4–6 days via trypsin. The culture media was switched to Opti-
MEM+2% FBS, and the cells were transfected with modified RNA encoding
either murine MYOD or GFP the following day, and for the following 2 days.
Media was supplemented with B18R and replaced 4 hr after each transfection.
After the third and final transfection, the media was switched to DMEM+3%
horse serum, and cultures were incubated for a further 3 days. Cells were
then fixed in 4% PFA and immunostained as previously described (Shea
et al., 2010). The percentage of myogenin-positive nuclei/total nuclei and
nuclei/MyHC-positive myotubes was quantified, with a minimum of 500 nuclei
counted per condition.
Technical Notes
Although reprogramming and directed differentiation via modified RNAs are
efficient processes, the protocols involved are nonetheless multistepped
and complex. It is therefore advised that in efforts to apply this methodology,
all steps of the protocols described herein are followed rigorously and quality
controlled. Foremost among these: templates for RNA synthesis must be
sequenced, and production of in vitro transcribed modified RNAs must be
quality controlled by gel electrophoresis and spectrophotometry. Critically,
the expression of proteins with modified RNAs must be confirmed by immu-
nostaining. Modified RNAs must also be tested for immunogenicity at multiple
points throughout the course of the experiment. Successful daily transfection
must be monitored by inclusion of modified RNA encoding a fluorescent
reporter throughout the course of experiments. Any reagents involved in sup-
porting pluripotency induction (media, feeder cells, etc.) should be tested for
their ability to support the growth of pluripotent cells prior to the start of exper-
iments. As is true of reprogramming by other methods, the quality of the start-
ing cells (e.g., passage number) impacts reprogramming via our technology.
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